NCT05643677View on ClinicalTrials.gov

Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

December 31, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2025

Conditions
Gastric Cancer
Interventions
DRUG

Fruquintinib

4 mg PO, QD (3 weeks on, 1 week off)

DRUG

Irinotecan

participants will receive irinotecan, 100 mg/m2, intravenous drip, day1 and day 14 of every 4 weeks

All Listed Sponsors
lead

Fujian Medical University

OTHER

NCT05643677 - Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter